HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

AbstractOBJECTIVE:
The aim of the study was to determine the differential expression patterns of the wingless-type (Wnt) pathway inhibitors Dkk3 (Dickkopf 3), SFRP1 (secreted frizzled-related protein 1), and SFRP4 in normal müllerian tissue and endometrial endometrioid adenocarcinoma specimens.
METHODS:
Messenger RNA (mRNA) and protein levels of the Wnt pathway inhibitors Dkk3, SFRP1, and SFRP4 were evaluated by real-time reverse transcription-polymerase chain reaction and Western blot analysis. A total of 87 human tissue specimens were obtained from 60 women who participated in Gynecologic Oncology Group protocol 210. Twenty-seven normal müllerian tissues, 32 early-stage, and 28 advanced-stage endometrial endometrioid cancer specimens were analyzed.
RESULTS:
Median age for this cohort was 60 years, with median body mass index of 32 kg/m. There was a difference in Dkk3 protein expression between normal müllerian tissues and primary endometrial endometrioid adenocarcinoma samples (P = 0.05). There was down-regulation of Dkk3, SFRP1, and SFRP4 mRNA expression in patients with high-grade disease (P = 0.08, 0.06, and 0.05, respectfully). Furthermore, a decrease in SFRP1 and SFPR4 mRNA expression was noted in patients with a diagnosis of locoregional and distant disease recurrence. Lastly, a trend toward decreased progression-free survival in patients with low Dkk3, SFRP1, and SFRP4 mRNA expression levels was noted.
CONCLUSIONS:
Wnt pathway inhibitor (Dkk3, sFRP1, and/or sFRP4) expression was down-regulated in patients with high-grade disease and was associated with locoregional and distant disease recurrence. Despite sample size (power) limitations, these results support previous preclinical studies and may suggest a therapeutic role for Wnt signaling in endometrial cancer.
AuthorsRamez N Eskander, Shamshad Ali, Thanh Dellinger, Heather A Lankes, Leslie M Randall, Nilsa C Ramirez, Bradley J Monk, Joan L Walker, Eric Eisenhauer, Bang H Hoang
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) Vol. 26 Issue 1 Pg. 125-32 (Jan 2016) ISSN: 1525-1438 [Electronic] England
PMID26397159 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
Chemical References
  • Adaptor Proteins, Signal Transducing
  • Biomarkers, Tumor
  • Chemokines
  • DKK3 protein, human
  • Intercellular Signaling Peptides and Proteins
  • Membrane Proteins
  • Proto-Oncogene Proteins
  • RNA, Messenger
  • SFRP1 protein, human
  • SFRP4 protein, human
Topics
  • Adaptor Proteins, Signal Transducing
  • Aged
  • Biomarkers, Tumor (genetics, metabolism)
  • Blotting, Western
  • Carcinoma, Endometrioid (genetics, metabolism, pathology)
  • Chemokines
  • Cohort Studies
  • Endometrial Neoplasms (genetics, metabolism, pathology)
  • Female
  • Follow-Up Studies
  • Humans
  • Intercellular Signaling Peptides and Proteins (genetics, metabolism)
  • Membrane Proteins (genetics, metabolism)
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local (genetics, metabolism, pathology)
  • Neoplasm Staging
  • Prognosis
  • Proto-Oncogene Proteins (genetics, metabolism)
  • RNA, Messenger (genetics)
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Rate
  • Tumor Cells, Cultured
  • Wnt Signaling Pathway

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: